Clinical Trials Browser

Phase 1/2 × OTHER × ON 01910 × Clear all

NCT03786237 2026-02-24

Rigosertib for RDEB-SCC

Phase 1/2 Completed

Carcinoma, Squamous Cell, Epidermolysis Bullosa Dystrophica

NCT04263090 2024-05-09

Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment

Phase 1/2 Completed

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis